Selected IIR references (for other abstracts, see Lists of IIR Publications):

Svenson et al. Specific binding of interleukin 1 (IL-1)b and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine 1993; 5:427-435.

Diamant et al. Stimulation of the B9 hybridoma cell line by soluble interleukin-6 receptors. J Immunol Methods 1994; 173:229-235.

Hansen et al. Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors. Eur J Immunol 1995; 25:348-354.

Svenson et al. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors. Eur J Immunol 1995; 25:2842-2850.

Diamant et al. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors. Leuk Res 1996; 20:291-301.

Diamant et al. Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett 1997; 412:379-384.

Saldeen et al. Liposome-mediated transfer of IL-1 receptor antagonist gene to dispersed islet cells does not prevent recurrence of disease in syngeneically transplanted NOD mice. Cytokine 2000;12:405-8.

Chenoufi et al. Increased mRNA expression and protein secretion of interleukin-6 in primary human osteoblasts differentiated in vitro from rheumatoid and osteoarthritic bone. J Cell Biochem 2001; 81: 666-78.

Nicoletti et al. Serum levels of the interferon-g-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type 1 diabetes. Diabetologia 2001; 44: 309-11.

Nicoletti et al. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 2001; 57: 342-4.

Li et al. Prevention of murine experimental autoimmune orchitis by recombinant human Interleukin-6. Clin Immunol 2002; 102: 135-7.

Kaneko et al. Proinflammatory effects of exogenously administered interleukin 10 in experimental autoimmune orchitis. Cytokine 2003;22:50-3.

Nersting et al. Maturation of human dendritic cells by monocyte-conditioned medium is dependent on trace amounts of lipopolysaccharide inducing tumour necrosis factor. Immunol Lett 2003;89:59-65.

Nicoletti et al. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulitis by a recombinant IL-18-binding protein: Fc construct. Eur J Immunol 2003;33:2278-86.

Pignatti et al. High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clin Exp Immunol 2003;131:355-63.

Woetmann et al. Protein Phosphatase 2A (PP2A) Regulates Interleukin-4-mediated STAT6 Signaling. J Biol Chem 2003;278:2787-91.

Galle P, Hougs L, Barington T, Svenson A, Svejgaard A, Thomsen AR, Bendtzen K, Hansen MB. Knocking out IL-6 by vaccination. Eur J Immunol 2004;34:291-300.

Galle P, Svenson M, Bendtzen K, Hansen MB. High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors. Eur J Immunol 2004;34:3267-3275.

Roeske-Nielsen et al. Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. Immunol Lett 2004;91:205-11.